Sign in

ARMP on NYSE

Armata Pharmaceuticals, Inc.

American biological products company based in Glen Allen, active since 19892

In its 2026 annual report the company says: “We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.”4 Its shares trade on NYSE under the symbol ARMP.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerARMP on NYSE2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersGlen Allen, United States2
  • Incorporated inWA3
  • Business address5005 Mcconnell Ave, Los Angeles, Ca 900663
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formProfit Corporation2
  • LEI549300QM1VCWH8KT0S212
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 711 CAPITOL WAY S STE 204, 98501-1267 Olympia, United States2
  • Registered withCorporations Division (Office of the Secretary of State), 601 166 3992

See how the biggest companies compare on our leaderboards

We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$36.6M in 2025+85% since 2019
-$60.0M-$40.0M-$20.0M02019: -$19.8M-$19.8M20192020: -$21.6M-$21.6M2020+9%2021: -$23.8M-$23.8M2021+10%2022: -$36.9M-$36.9M2022+55%2023: -$40.9M-$40.9M2023+11%2024: -$42.4M-$42.4M2024+4%2025: -$36.6M-$36.6M2025−14%
Net income5678910-$173.8M in 2025+792% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$19.5M-$19.5M20192020: -$22.2M-$22.2M2020+14%2021: -$23.2M-$23.2M2021+4%2022: -$36.9M-$36.9M2022+59%2023: -$69.0M-$69.0M2023+87%2024: -$18.9M-$18.9M2024−73%2025: -$173.8M-$173.8M2025+819%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Grant and award revenue$4.9M$5.2M
Research and development$23.7M$34.4M
General and administrative$12.4M$13.2M
Impairment expense$5.4M
Total operating expenses$41.5M$47.6M
Operating loss-$36.6M-$42.4M
Interest income$388.0K$697.0K
Interest expense-$16.6M-$10.7M
Change in fair value of the Convertible Loan-$121.0M$31.4M
Gain on debt and the Convertible Loan extinguishments$2.2M
Total other income (expense), net-$137.2M$23.5M
Net loss-$173.8M-$18.9M
Net loss per share, basic-$4.80-$0.52
Weighted average shares outstanding, basic36.2M shares36.2M shares
Net loss per share, diluted-$4.80-$0.89
Weighted average shares outstanding, diluted36.2M shares59.1M shares

Compare Armata Pharmaceuticals, Inc. with another company

Corporate structure

Armata Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Armata Pharmaceuticals, Inc.

  • Innoviva, Inc. Filed SCHEDULE 13D/A on Armata Pharmaceuticals, Inc., latest May 13, 2026 (11 filings since Nov 1, 2021)
  • Armata Pharmaceuticals, Inc. Glen Allen, Virginia, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Armata Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$26.2M10 Dec 31, 2025$26.4M10 Dec 31, 2024−0.6%
Accumulated depreciation$14.0M10 Dec 31, 2025$13.1M10 Dec 31, 2024+6.8%
Property and equipment, net$12.2M10 Dec 31, 2025$13.2M10 Dec 31, 2024−7.9%
Operating-lease assets (leased space)$33.9M10 Dec 31, 2025$41.7M10 Dec 31, 2024−18.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.7M10 Dec 31, 2025$9.3M10 Dec 31, 2024−6.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.5M10 Dec 31, 2025$3.5M10 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$10.3M10 Dec 31, 2025$10.3M10 Dec 31, 20240%

Properties, in its own words

Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066. On October 28, 2021, we entered into a lease for approximately 56,300 square feet of office, research and development and manufacturing space at our headquarters under a non-cancellable lease. The 2021 Lease payment start date was May 1, 2022, and the total lease term is for 16 years and runs through 2038. Office space and research laboratories have been occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 square feet) fully constructed and occupied in the second half of 2024.

We also have a facility located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease approximately 35,500 square feet of laboratory and office space. The Marina del Rey Lease expires on December 31, 2031. The facility includes 19,500 square feet of BSL2 laboratory space, and approximately 3,000 square feet of cGMP laboratory space. We are actively seeking a sub-tenant to take over the remaining term of the Marina del Rey Lease.

The rest of Item 2

In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development.

We believe that our existing office and laboratory space is sufficient to meet our needs for the foreseeable future. Additionally, we believe our McConnell Facility, offering 10,000 square feet of manufacturing capacity, will allow us to pursue contract manufacturing opportunities for phage and potentially other advanced biologics.

Item 2 of the 10-K filed Mar 25, 2026.4

Leadership

Who has led Armata Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. H. Stewart Parker2006–2008
  2. Bg Susan Robinson2008–2010
  3. Philip J. Young2014
  4. Michael Scott Salka2015–2017
  5. Paul C. Grint2017
  6. Todd Patrick2019–2021
  7. Brian Varnum2021–2022
  8. Deborah Birx2023–now

Chair

  1. Jeremy Curnock Cook2006–2008

President

  1. H. Stewart Parker2006–2008
  2. Bg Susan Robinson2008–2010
  3. Philip J. Young2014
  4. Brian Varnum2019–2022

Chief financial officer

  1. David J. Poston2006–2010
  2. Kelley A. Wendt2014
  3. Steven Robert Martin2016–2021
  4. Julianne Averill2023

Chief operating officer

  1. Wendy S. Johnson2015
  2. Igor Bilinsky2017
2010201520202025
Board members and other officers (35)

Former names

  • AmpliPhi Biosciences CorpFeb 25, 2013 to May 8, 20193
  • TARGETED GENETICS CORP /WA/Jul 2, 1996 to Feb 11, 20113

Timeline

  1. Sep 23, 20268-K Other events57
  2. Sep 14, 20268-K Regulation FD disclosure58
  3. Aug 12, 20268-K Results of operations59
  4. Jul 20, 20268-K Executive or director change60
  5. Jul 20, 20268-K Regulation FD disclosure61
  6. Jul 13, 20268-K Regulation FD disclosure62
  7. Jun 24, 20268-K Executive or director change63
  8. Jun 23, 20268-K Other events64
  9. Jun 16, 20268-K Shareholder vote65
  10. May 13, 20268-K Entered a material agreement; Results of operations; New debt or obligation66
  11. May 7, 20268-K Regulation FD disclosure67
  12. Apr 27, 20268-K Executive or director change; Regulation FD disclosure68
  13. Jul 19, 2023New chief executive Deborah Birx becomes CEO13
  14. Aug 3, 2021New chief executive Brian Varnum becomes CEO14
  15. May 16, 2019New chief executive Todd Patrick becomes CEO15
  16. Sep 11, 2017New chief executive Paul C. Grint becomes CEO16
  17. Aug 6, 2015New chief executive Michael Scott Salka becomes CEO17
  18. Feb 18, 2014New chief executive Philip J. Young becomes CEO18
  19. Nov 17, 2008New chief executive Bg Susan Robinson becomes CEO19
  20. Jun 13, 2006New chief executive H. Stewart Parker becomes CEO20
  21. Mar 9, 1989Founded Armata Pharmaceuticals, Inc. is founded2

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.42) a share, on Nov 12, 2025.69

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results59
  2. May 13, 2026Reported quarterly or annual results66
  3. Mar 25, 2026Reported quarterly or annual results70
  4. Nov 12, 2025Reported quarterly or annual results71
  5. Aug 12, 2025Reported quarterly or annual results72
  6. May 14, 2025Reported quarterly or annual results73
  7. Mar 21, 2025Reported quarterly or annual results74
  8. Nov 13, 2024Reported quarterly or annual results75

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

204 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 63 insider forms, 11 large holders, 42 other. The latest 20:

  1. Sep 23, 20268-K EDGAR
  2. Sep 14, 20268-K EDGAR
  3. Aug 12, 202610-Q EDGAR
  4. Aug 12, 20268-K EDGAR
  5. Jul 20, 20268-K EDGAR
  6. Jul 20, 20268-K EDGAR
  7. Jul 14, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Jul 13, 20268-K EDGAR
  9. Jul 13, 2026S-8 EDGAR
  10. Jun 24, 20268-K/A EDGAR
  11. Jun 23, 20268-K EDGAR
  12. Jun 16, 20268-K EDGAR
  13. May 13, 2026SCHEDULE 13D/A EDGAR
  14. May 13, 202610-Q EDGAR
  15. May 13, 20268-K EDGAR
  16. May 7, 20268-K EDGAR
  17. Apr 28, 20264 OWNERSHIP DOCUMENT EDGAR
  18. Apr 28, 20263 OWNERSHIP DOCUMENT EDGAR
  19. Apr 27, 2026ARS EDGAR
  20. Apr 27, 2026DEF 14A EDGAR

The 204 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 31, 2022Innoviva, Inc.DirectorBuy5,385,208$5.00$26.9MForm 4
Feb 9, 2022Innoviva Strategic Opportunities LLCDirectorBuy3,614,792$5.00$18.1MForm 4
Oct 29, 2021Innoviva Strategic Opportunities LLCDirectorBuy1,212,122$3.30$4.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Deborah BirxM.D.70$562.4K$1.2M77
2025Pierre KymePh.D.$412.0K$791.6K77
2025David House42$360.5K$554.8K77
2024Chief Executive Officer$546.0K$1.8M77
2024Chief Business Officer$379.5K$823.6K77
2024Senior Vice PresidentFinance and$131.2K$319.4K77

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 53. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Madison Asset Management, LLC2,107,175$13.7M0.2%−500
BlackRock, Inc.559,986$3.6M0.0%+494,936
Vanguard Capital Management LLC487,968$3.2M0.0%+121,940
Millennium Management LLC470,500$3.0M0.0%+212,508
Geode Capital Management, LLC270,550$1.8M0.0%+155,995
Dauntless Investment Group, LLC203,891$1.3M2.3%+113,311
State Street Corp129,600$839.8K0.0%+78,800
Northern Trust Corp89,791$581.8K0.0%+65,145
Vanguard Portfolio Management LLC81,354$527.2K0.0%New
Edgewood Management LLC80,000$518.4K0.0%−20,000
Vanguard Fiduciary Trust Co79,495$515.1K0.0%+11,631
Grey Ledge Advisors, LLC50,000$324.0K0.1%+20,000
Renaissance Technologies LLC48,318$313.1K0.0%+9,822
Bridgeway Capital Management, LLC44,682$289.5K0.0%No change
SeaCrest Wealth Management, LLC41,524$269.1K0.0%No change
Bank of New York Mellon Corp29,749$192.8K0.0%New
Charles Schwab Investment Management Inc28,857$187.0K0.0%New
Hudson Bay Capital Management LP17,584$113.9K0.0%No change
Nuveen, LLC15,905$103.1K0.0%New
New York State Common Retirement Fund15,400$99.8K0.0%New
UBS Group AG13,697$88.8K0.0%+9,348
Captrust Financial Advisors13,140$85.1K0.0%No change
Deutsche Bank Ag\11,966$77.5K0.0%New
Bank Of America Corp /de/11,305$73.3K0.0%−409
XTX Topco Ltd10,826$70.2K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Armata Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARArmata Pharmaceuticals, Inc.1
  • CIK0000921114
  • Employer ID (EIN)91-15495684
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inWashington4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5005 Mcconnell Ave, Los Angeles, CA 900661
  • Phone310-665-29281
  • Shares outstanding37,181,979 as of Aug 6, 202612
  • Public float$21.1M as of Jun 30, 20254
  • AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 6, 19961
  • Filings1,158 in all: 8-K (317), 4 (218), 10-Q (79), 3 (40), CORRESP (37), SC 13D/A (34), UPLOAD (33), DEF 14A (31)1
    All 60 form types

    SC 13G/A (27), SC 13G (24), 10-K (21), S-1/A (21), 424B3 (20), EFFECT (20), S-8 (19), PRE 14A (17), S-3 (17), CT ORDER (14), DEFA14A (12), 424B5 (11), POS AM (11), S-3/A (11), ARS (10), SC 13D (10), S-8 POS (9), 10-Q/A (8), 8-K/A (7), S-1 (7), REGDEX (6), 10-K/A (5), 10-K405 (5), 10-12G/A (4), 4/A (4), D (4), FWP (4), SCHEDULE 13D/A (4), 3/A (3), 424B4 (3), 10-K405/A (2), 5 (2), D/A (2), DEFM14A (2), NT 10-K (2), NT 10-Q (2), POS EX (2), PREM14A (2), RW (2), 10-12G (1), 15-12G (1), 15-12G/A (1), 25 (1), 424B2 (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), CERTNYS (1), PRER14A (1), S-1MEF (1), SC 13E3 (1), SC 13E3/A (1)

  • Latest filingsAnnual report (10-K) Mar 25, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 27, 2026
    Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

ClassSymbolExchange
Common StockARMPNYSE American

From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Armata Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 25, 2026: 29 risks under these headings, as written.4

  • Risks Related to Our Financial Condition and Need for Additional Capital
  • There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates.
  • We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.
  • If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the Department of Defense and related entity standards could impact our ongoing and future development financing awards from the U.S. government.
  • Risks Related to Our Business
  • We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.
  • Results from interim, “top-line,” and preliminary data, or preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials and are subject to audit and verification procedures that could result in material changes in the final data.
  • Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and commercialize our product candidates.
  • We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.
  • If we are unable to obtain FDA approval of our products, we will not be able to commercialize our products in the United States.
  • We may conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials.
  • We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates.
The other 19 risks
  • We rely on third parties to conduct our clinical trials and to obtain materials or supplies necessary to conduct trials or to manufacture our product candidates, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.
  • Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • We face potential liability related to the privacy of health information we may obtain from the patients in our clinical trials if we fail to comply with privacy laws.
  • We face potential risks associated with future changes in laws and policies, including the availability of government funding for grants, staffing and funding of regulatory agencies.
  • The use or anticipated use of artificial intelligence (“AI”) technologies, including generative AI, by us or third parties, may increase or create new operational risks.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Risks Related to Our Industry
  • There is a high rate of failure inherent in drug discovery and development, and failure can occur at any point in the process, including in later stages after substantial investment.
  • We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability.
  • Current and future healthcare reform measures may affect our results of operations.
  • Risks Related to Our Common Stock
  • Innoviva, our principal stockholder, beneficially owns greater than 50% of our outstanding shares of Common Stock, which causes us to be deemed a “controlled company” under the rules of NYSE. In addition, Innoviva’s interests in our business may be different than our other stockholders.
  • The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations, and/or require us to relinquish rights to our technologies or product candidates.
  • General Risk Factors
  • Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.
  • Our operations could be disrupted by failure of our information systems or by successful cyber-attacks.

Legal proceedings

From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject us to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
    SEC EDGAROther events
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
    SEC EDGAROther events
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77